

March 6, 2014
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer

Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors

SymBio Pharmaceuticals Limited (“the Company”) announces that at a Board of Directors’ meeting held today, it has decided to submit, for discussion at the 9th Ordinary General Meeting of Shareholders that will be held on March 27, 2014 (“the Shareholders’ Meeting”), a proposal as to the “Partial Amendment to the Articles of Incorporation” and “Election of six (6) Directors.”

1. Partial amendment to the Articles of Incorporation

(1) Reason for the amendment

We propose to reduce the term of the Company’s Directors from two (2) years to one (1) year, in order to clarify management responsibilities of the Company’s Directors and to put in place a management structure that is better equipped to deal with rapid changes in the business environment. At the same time, we propose to delete the detailed rule as to Directors’ terms of office.

(2) Details of amendment

The details of proposed amendment are as follows:

(Amended portions shown with underlines)

Current Articles of Incorporation	Proposed amendment
Chapter 4 Directors and Board of Directors (The term of office of Directors) Article 22 The terms of office of Directors shall expire at the close of the Ordinary General Meeting of Shareholders held with respect to the last business year ending within <u>two (2) years</u> of after their appointment. <u>2. The term of office of the Director who was appointed to fill a vacancy or to be an addition to the Board shall expire at the same time as the incumbent Directors.</u>	Chapter 4 Directors and Board of Directors (The term of office of Directors) Article 22 The terms of office of Directors shall expire at the close of the Ordinary General Meeting of Shareholders held with respect to the last business year ending within <u>one (1) year</u> of after their appointment. (Delete)

2. Election of six (6) Directors

(1) Reason for election

Once “Partial amendment to the Article of Incorporation” is passed at the 9th Shareholders’ Meeting held on March 27, 2014, six (6) Directors will reach the end of the term at the conclusion of this Shareholders’ Meeting. We therefore propose, conditional upon the aforementioned proposal passing, the election of the following candidates.

(2) Election of Directors

Name	Reappointment/New	Current title
Fuminori Yoshida	Reappointment	Representative Director, President and Chief Executive Officer
Takako Ebata	Reappointment	Outside Director
Lowell Sears	Reappointment	Outside Director
George Morstyn	Reappointment	Outside Director
Milton Grannatt	Reappointment	Outside Director
George Vandeman	New appointment	—

※ Takako Ebata, Lowell Sears, George Morstyn, Milton Grannatt and George Vandeman are the Outside Directors as defined in the Companies Act in Japan.

(3) The brief profile of the new candidate is as follows:

Name (Date of birth)	Career summary	
George Vandeman (January 16, 1940) ※	June 1966	Join in Latham & Watkins LLP
	January 1982	Senior Partner (Public relations attorney), Latham & Watkins LLP
	July 1995	Senior Vice President and General Counsel, Amgen Inc. (U.S.)
	July 2005	Principal, Vandeman & Company (current)
	September 2005	Director (Outside) of the Company (resigned on June 2008)
	April 2006	Director, Value Vision Media, Inc.

※ We request the election of George Vandeman as Outside Director so that he may give independent, objective advice regarding the management of the Company to the management, based on his plentiful knowledge and experience in law, Japan-U.S. pharmaceutical industry and many other industries.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125